leadf
logo-loader
viewMydecine Innovations Group Inc
(
OTC:MYCOFFRA:0NFANEO:MYCO
)

Mydecine Innovations Group: Research program moving to the next level

Mydecine Innovations Group is a biotech and life sciences company developing and commercializing new therapies for mental health and other conditions. The company has two therapies which are at phase II clinical trial stage. Both of these use Mydecine’s proprietary formulation MYCO-001, which is a purified form of psilocybin, a psychedelic compound derived from mushrooms.

Since our initiation of research coverage in June 2021, Mydecine has made significant new announcements on the progress of the business. The company announced a five-year research agreement with Johns Hopkins University School of Medicine (Sedar release Aug 18th 2021), which extends the length and scope of Mydecine’s existing collaboration with Johns Hopkins. The program will continue to research the use of psychedelics for nicotine addiction and will add further projects.

Johns Hopkins is a world-leading medical research institution, consistently ranked among the top three in the US, and we argue that this partnership provides a strong platform for furthering Mydecine’s proprietary drug developments.

Also in recent weeks, the company announced second-quarter results. These are in line with our expectations, and we reiterate our existing financial forecasts (details p3-4).

 

Quick facts: Mydecine Innovations Group Inc

Follow
OTC:MYCOF

Price: 0.2757 USD

Market Cap: $65.14 m

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Mydecine Innovations Group outlines plan for MYCO-001 Phase 2/3 Smoking...

Mydecine Innovations Group Inc (OTC:MYCOF, FRA:0NFA, NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) (NEO:MYCO) CEO Joshua Bartch tells Proactive it has partnered with Principal Investigator Dr Matthew Johnson of Johns Hopkins University on a study evaluating the administration of its lead drug candidate...

2 weeks, 3 days ago

5 min read